Live Breaking News & Updates on Analyst Recommendations For Jazz Pharmaceuticals

Stay updated with breaking news from Analyst recommendations for jazz pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Jazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded by StockNews.com to "Buy"

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock. ....

United States , Thomson Reuter , Brucec Cozadd , Piper Sandler , Securities Exchange Commission , Jazz Pharmaceuticals , Norges Bank , Analyst Recommendations For Jazz Pharmaceuticals , Needham Company , Alphacentric Advisors , Walleye Capital , Evergreen Capital Management , Quent Capital , Jazz Pharmaceuticals Get Rating , Get Rating , Exchange Commission , Capital Management ,

The Goldman Sachs Group Lowers Jazz Pharmaceuticals (NASDAQ:JAZZ) to Neutral

The Goldman Sachs Group downgraded shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Rating) from a buy rating to a neutral rating in a research note published on Wednesday morning, MarketBeat.com reports. The Goldman Sachs Group currently has $196.00 target price on the specialty pharmaceutical company’s stock, down from their prior target price of $202.00. JAZZ […] ....

United States , Thomson Reuter , Brucec Cozadd , Jazz Pharmaceuticals , Norges Bank , Analyst Recommendations For Jazz Pharmaceuticals , Jazz Pharmaceuticals Company Profile Get Rating , Needham Company , Alphacentric Advisors , Cantor Fitzgerald , Walleye Capital , Goldman Sachs Group , Evergreen Capital Management , Quent Capital , Get Rating , Capital Management , Pharmaceuticals Company Profile , Nasdaq Jazz , The Goldman Sachs Group Inc ,

Jazz Pharmaceuticals (NASDAQ:JAZZ) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Rating) in a note issued to investors on Thursday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock. Several other research firms also recently weighed in on JAZZ. SVB Leerink reduced their target price on Jazz Pharmaceuticals from $230.00 to $200.00 […] ....

Thomson Reuter , Brucec Cozadd , Piper Sandler , Securities Exchange Commission , Jazz Pharmaceuticals , Norges Bank , Analyst Recommendations For Jazz Pharmaceuticals , Needham Company , Alphacentric Advisors , Cantor Fitzgerald , Walleye Capital , Evergreen Capital Management , Quent Capital , Jazz Pharmaceuticals Get Rating , Jazz Pharmaceuticals Plc , Get Rating , Exchange Commission , Capital Management , Pharmaceuticals Plc , Nasdaq Jazz , Initiated Coverage , Stocknews Com ,

Royal Bank of Canada Trims Jazz Pharmaceuticals (NASDAQ:JAZZ) Target Price to $214.00

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Rating) had its target price decreased by Royal Bank of Canada from $216.00 to $214.00 in a report released on Wednesday morning, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the specialty pharmaceutical company’s stock. A number of other equities research analysts also recently weighed in […] ....

Brucec Cozadd , Goldman Sachs Group Inc , Jazz Pharmaceuticals , Analyst Recommendations For Jazz Pharmaceuticals , Needham Company , Polaris Capital Management , Farallon Capital Management , Goldman Sachs Group , Jazz Pharmaceuticals Get Rating , Jazz Pharmaceuticals Plc , Royal Bank , Get Rating , Truist Financial , Sachs Group , Capital Management , Deep Track Capital , Pharmaceuticals Plc , Nasdaq Jazz , Lower Price Target , Royal Bank Of Canada ,